RWE Study Utilizing the Cala Trio Device in Patients With Essential Tremor

Inclusion Criteria: * Age ≥22years * Aetna commercial fully insured OR Medicare Advantage population (inclusion of Medicare is contingent upon additional internal approvals) * Two ICD claims for ET, at least seven days apart, in the last three years OR one ICD claim for ET followed by at least one dispensed pharmaceutical treatment for ET * Contraindication to standard pharmacological therapy (Asthma, COPD, 1stor 2nddegree heart block) OR indicator of poor pharmacological acceptability as evidenced by drug switching behaviors OR indicator of drug resistance as evidenced by the use of third-line drug therapies including Clozapine, Mirtazapine, Gabapentin, Topiramate, Clonazepam or Alprazolam * Willing and able to provide informed consent to participate in the study * Willing and able to follow study protocol requirements * Patients with PCP or neurologist provider encounter in past 18months Exclusion Criteria: * ICD-10 evidence of a pacemaker or defibrillator or a procedure code indicating pacemaker implantation, electrode renewal or calibration * ICD-10 evidence of a deep brain stimulator or a procedure code indicating DBS implantation * CPT/HCPCS evidence of thalamotomy, gamma-knife radio surgical thalamotomy * NDC and CPT evidence of botulinum toxin the last 6 months as therapeutic injection in the upper limb * Pregnant during the enrollment period * Evidence of Parkinson's Disease * Evidence of epilepsy * Formal diagnosis of hypothyroidism and treatment * Formal diagnosis of hyperthyroidism without evidence of treatment * Formal diagnosis of dementia * Evidence of Treatment with thyroid hormone supplements (2 Rx claims 28 or more days apart) or evidence of hyperthyroidism (2+ claims, 28 days or more apart)